Amarin Corporation PLC (NASDAQ:AMRN) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other brokerages have also recently commented on AMRN. Zacks Investment Research upgraded Amarin Corporation PLC from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research note on Tuesday, July 11th. BidaskClub cut Amarin Corporation PLC from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a research note on Thursday, August 3rd. Jefferies Group LLC reiterated a “buy” rating and issued a $7.00 price target on shares of Amarin Corporation PLC in a research note on Thursday, August 3rd. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a research note on Tuesday, September 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. Amarin Corporation PLC has an average rating of “Hold” and an average price target of $7.75.

Shares of Amarin Corporation PLC (NASDAQ:AMRN) traded up $0.04 on Friday, hitting $3.60. The company’s stock had a trading volume of 1,360,000 shares, compared to its average volume of 1,340,000. Amarin Corporation PLC has a 12 month low of $2.76 and a 12 month high of $4.47. The company has a debt-to-equity ratio of -1.48, a quick ratio of 1.46 and a current ratio of 1.63.

Amarin Corporation PLC (NASDAQ:AMRN) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. The company had revenue of $47.10 million for the quarter, compared to analyst estimates of $45.85 million. The company’s revenue for the quarter was up 45.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.08) EPS. equities research analysts predict that Amarin Corporation PLC will post -0.2 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2017/11/04/amarin-corporation-plc-amrn-upgraded-at-valuengine.html.

In related news, insider Steven B. Ketchum sold 63,479 shares of the business’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $3.48, for a total value of $220,906.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 3.72% of the company’s stock.

A number of institutional investors have recently made changes to their positions in AMRN. Wells Fargo & Company MN increased its holdings in Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Amarin Corporation PLC by 27.1% in the first quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 7,580 shares during the last quarter. Westside Investment Management Inc. increased its holdings in Amarin Corporation PLC by 1.1% in the second quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 300 shares during the last quarter. Perkins Capital Management Inc. increased its holdings in Amarin Corporation PLC by 20.3% in the second quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 7,000 shares during the last quarter. Finally, Stevens Capital Management LP bought a new stake in Amarin Corporation PLC in the third quarter valued at about $229,000. 37.76% of the stock is owned by hedge funds and other institutional investors.

About Amarin Corporation PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.